Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. - Wikidata - wikimedia - TriplyDB

Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment.

Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment.

http://www.wikidata.org/entity/Q42482098

about

Understanding dendritic cells and their role in cutaneous carcinoma and cancer immunotherapy Aldara activates TLR7-independent immune defence Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy.Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model.Resiquimod and other immune response modifiers as vaccine adjuvants.Plasmacytoid dendritic cells suppress HIV-1 replication but contribute to HIV-1 induced immunopathogenesis in humanized mice.Roles of the immune system in skin cancer.Immunomodulation by imiquimod in patients with high-risk primary melanoma Brucella spp. Lumazine Synthase Induces a TLR4-Mediated Protective Response against B16 Melanoma in Mice.Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream.Plasmacytoid dendritic cells lead the charge against tumors.Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection.Targeting Toll-like receptor 2 inhibits growth of head and neck squamous cell carcinoma.Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma Imiquimod attenuates the growth of UVB-induced SCC in mice through Th1/Th17 cells.The Immunomodulatory Small Molecule Imiquimod Induces Apoptosis in Devil Facial Tumour Cell Lines Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells.The small-molecule immune response modifier imiquimod--its mode of action and clinical use in the treatment of skin cancer.Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients.Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword?Therapeutic use of Aldara in chronic myeloid leukemia.Synergistic enhancement of cellular immune responses by the novel Toll receptor 7/8 agonist 3M-007 and interferon-γ: implications for therapy of cutaneous T-cell lymphoma.Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cells The use of reflectance confocal microscopy for monitoring response to therapy of skin malignancies.Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant.Significance of toll-like receptors expression in tumor growth and spreading: a short review Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling.Harnessing human dendritic cell subsets for medicine.Dendritic cell subsets as vectors and targets for improved cancer therapy Dendritic cells and immunity against cancer.Plasmacytoid dendritic cells and cancer.Pattern recognition receptors in immune disorders affecting the skin.Human dendritic cell functional specialization in steady-state and inflammation.Disseminated molluscum contagiosum in a HIV-positive child. Improvement after therapy with 5% imiquimod.Plasmacytoid dendritic cells, a role in neoplastic prevention and progression.Imiquimod in dermatology: an overview.Tumour necrosis factor-α plays a significant role in the Aldara-induced skin inflammation in mice.Toll-like receptors and cutaneous melanoma.

P2860

Q27004702-E1401EAB-B4E6-44EA-BF64-07111156CDA7 Q28286677-1305C018-2313-4340-837C-B4116F1994C7 Q33302568-45874F57-4113-455A-8933-CE0A37D90737 Q33479314-2C992B5A-E1B5-4531-B337-7DA97DF5ACBB Q33587443-F0EDA611-8B7E-46AD-8C54-86266F17293C Q34700325-B5F831FA-023A-4DA8-A4D5-55F6A5B2B040 Q35215887-F3553ABE-ABDD-4684-AD7F-6E41F6B45D62 Q35403714-14B8F486-35DF-4AEB-8AC3-836A5736723A Q35590166-B0B1CBF4-8E9E-41E3-A673-B3C3A6B7FB4B Q35606746-2539960F-B11F-40E1-8B8B-C1858EC9F0DA Q35632513-BB98894D-3B88-4294-80C1-91BACBFE4B93 Q35699010-FA86D086-3AA5-4066-9842-7F9356819A21 Q35724734-7D6F7E98-A0D7-40BC-92A8-F330ADE376FD Q35833184-81779C53-5063-4A49-97F3-9A1BAAE1AB70 Q36070459-F83FCE1B-E879-46C5-8353-894B784E183E Q36096165-71D817A5-FC91-4A9C-BC62-F2C4B1981B00 Q36218717-7DED225E-FEBF-4997-ACB5-D9B32FDFD1E7 Q36229384-FCA74CBB-BAE0-4F19-B575-FE25F2428989 Q36379372-6ACF24D3-5816-449C-ADFE-FBF591708B92 Q36547213-29798262-4887-4155-8A5C-59489FA32381 Q36557953-A7A56716-FE30-475A-B965-8ED9B705B2E0 Q36718548-72CE1B47-1AE9-4915-948C-C9709ED34A03 Q36730742-9D88BC79-5F4E-46BE-9934-C240594E0E55 Q36839509-0A369387-D489-49C2-BF8D-08783218B12F Q36873162-7D3F9E4A-7445-4B73-8CA1-EB72E3507E68 Q36916400-8945785A-3FA1-40ED-A187-7201A40146D3 Q36973053-AE0455A7-8D91-4573-BAA2-B8A34D1CBDB3 Q37421540-66D63B83-ABB0-492A-AAEF-7167EA049846 Q37435264-77529D48-0594-4E4A-9FDA-C1471B383CCB Q37700841-EBCA79D4-B9C9-4B53-B313-9C8697AEFE2F Q37758502-5F058097-1BD8-4CB0-926D-8A750A9122CC Q37821074-767CAE78-1453-4670-8294-CB5F34C97146 Q37897799-032C35C8-8206-47B4-A74D-74A768A9AF81 Q37991471-0FFCEED1-4CFE-4CD4-8CBE-CDA293EA9194 Q38205437-B6833367-DDCA-43D3-84CC-8CF76576E57F Q38268603-094A2D3D-43C6-45C8-B6DD-C6600F03FAFB Q38294189-50A96ECB-087D-4DE9-8BA8-A94CB72B2C31 Q38888889-F9C57511-8A25-41DA-B1A1-F5BC25AB5C12 Q38937859-8DA0EE4E-8089-4E1B-A9FC-CF742E7C6CA6 Q39023996-B093D616-6A09-4445-A4D2-6807F525E198

P2860

Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment.

http://www.wikidata.org/entity/Q42482098

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Disease-independent skin recru ...... following imiquimod treatment.

@en

Disease-independent skin recru ...... following imiquimod treatment.

@nl

type

label

Disease-independent skin recru ...... following imiquimod treatment.

@en

Disease-independent skin recru ...... following imiquimod treatment.

@nl

prefLabel

Disease-independent skin recru ...... following imiquimod treatment.

@en

Disease-independent skin recru ...... following imiquimod treatment.

@nl

P1433

Q42482098-47D195D2-B38F-4670-BAE4-FC3AC6D0737D

P1476

Q42482098-C7DBB430-8DC3-4D94-8958-FAFAE98DF721

P2093

Q42482098-244DCE4E-5427-48D5-84E8-8899264E8012

Q42482098-72540BAC-F3FB-4537-85E9-F9864387A44D

Q42482098-86725DF7-CD9D-4492-BC4B-4811E880EAE1

Q42482098-B6D3EE02-D1FF-4543-BF35-B3876201892C

Q42482098-EDF5E254-3E60-484F-9A64-B8DC26D6F61D

Q42482098-EF0AC9CB-5F35-49F5-9B21-B1CDFEBD59C4

P2860

Q42482098-0F578628-449D-4CE7-970C-C920DD5B3097

Q42482098-132F06EF-ADB5-4FAC-AD4F-00EC0A4EC7BA

Q42482098-1345F487-10D1-4489-83EC-00198E382EA0

Q42482098-1A16FBD9-C77B-4F73-847C-B2F439133BE1

Q42482098-2484D889-BEB7-4CDA-B97D-B54A3627C21F

Q42482098-2746BACA-B555-4272-AD2F-C6F152AFA219

Q42482098-2C6EC270-94D1-44F2-A7CD-48E3E8CFCDAB

Q42482098-31CC5EC6-B7AC-414A-B685-19D7870148D9

Q42482098-372B0527-BC1B-4C34-AD9F-C4415F503AA0

Q42482098-48506480-BD68-47C3-B6D1-0B681A28915A

P304

Q42482098-EADD51D7-FBE5-4F02-BFE3-245884A51E7B

P31

Q42482098-2217AA29-87FC-4CAD-96FB-0E3DE5A1316B

P356

Q42482098-EB695230-CF16-4A0B-B1DF-72C011BE6ED7

P407

Q42482098-24DA83A1-5FA1-4735-B22B-2A38A0E8F0CB

P433

Q42482098-1D90B420-3440-49BE-BEB6-3E900F62EB4A

P478

Q42482098-64A45268-1D7D-45DD-A78C-196C81C474E1

P50

Q42482098-4EAE38EF-214E-4BB9-A63B-231998865450

P577

Q42482098-15C45644-2894-408D-A60B-3A30C8F41310

P5875

Q42482098-4082BAAD-6E69-42D3-9D70-664109B1FC38

P698

Q42482098-5B17EC62-FB47-43C9-975C-8CAD87ADBD44

P356

P1433

Journal of the National Cancer Institute

P1476

Disease-independent skin recru ...... following imiquimod treatment

@en

P2093

Elisabeth Laine

http://www.w3.org/2001/XMLSchema#string

Günter Burg

http://www.w3.org/2001/XMLSchema#string

Michel Gilliet

http://www.w3.org/2001/XMLSchema#string

Mirjam Beyeler

http://www.w3.org/2001/XMLSchema#string

Mirjana Urosevic

http://www.w3.org/2001/XMLSchema#string

Reinhard Dummer

http://www.w3.org/2001/XMLSchema#string

P2860

Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848

Cluster analysis and display of genome-wide expression patterns

The inducible CXCR3 ligands control plasmacytoid dendritic cell responsiveness to the constitutive chemokine stromal cell-derived factor 1 (SDF-1)/CXCL12

BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction

Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

Toll-like receptor control of the adaptive immune responses

Immunobiology of dendritic cells

Dendritic cells: specialized and regulated antigen processing machines

The nature of the principal type 1 interferon-producing cells in human blood

P304

1143-1153

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJI207

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

97

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7682739

http://www.w3.org/2001/XMLSchema#string

P698

16077073

http://www.w3.org/2001/XMLSchema#string